SOPH SOPHiA GENETICS SA

Nasdaq sophiagenetics.com


$ 3.89 $ 0.00 (0 %)    

Friday, 21-Nov-2025 09:33:06 EST
QQQ $ 585.54 $ -1.79 (-0.3 %)
DIA $ 459.08 $ -0.50 (-0.11 %)
SPY $ 653.89 $ -1.12 (-0.17 %)
TLT $ 89.50 $ -0.17 (-0.18 %)
GLD $ 374.38 $ 0.41 (0.11 %)
$ 3.89
$ 3.90
$ 3.87 x 100
$ 4.03 x 100
-- - --
$ 2.58 - $ 5.30
69,173
na
259.41M
$ 1.67
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 btig-maintains-buy-on-sophia-genetics-raises-price-target-to-7

BTIG analyst Mark Massaro maintains Sophia Genetics (NASDAQ:SOPH) with a Buy and raises the price target from $6 to $7.

 sophia-genetics-and-adam-innovations-partner-to-launch-ai-powered-liquid-biopsy-genomic-testing-and-develop-companion-diagnostic-for-cancer-care-in-japan

- A.D.A.M. Innovations, Japan's leading private genetic testing company, and SOPHiA GENETICS (NASDAQ:SOPH), an AI technolog...

 2-under-the-radar-health-tech-stocks-with-surging-momentum-scores

Two under-the-radar health-tech stocks are seeing their Momentum scores surge in Benzinga's Edge Stock Rankings.

Core News & Articles

Myriad Genetics (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (NASDAQ:SOP...

 sophia-genetics-affirms-fy2025-sales-guidance-of-72000m-76000m-vs-74200m-est-projects-adjusted-ebitda-loss-between-35m-39m

Sophia Genetics (NASDAQ:SOPH) affirms FY2025 sales outlook from $72.000 million-$76.000 million to $72.000 million-$76.000 mill...

 sophia-genetics-q2-eps-033-misses-023-estimate-sales-18323m-beat-17480m-estimate

Sophia Genetics (NASDAQ:SOPH) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION